Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IB004 is an early-stage therapeutic candidate being developed by Interactome Biotherapeutics, utilizing small extracellular vesicles (sEVs), commonly referred to as exosomes. The drug is produced using the company's proprietary Native Nano Platform, which aims to harness the natural biological properties of exosomes for therapeutic delivery or intercellular communication. Currently in the discovery phase, the specific molecular targets, active ingredients, and primary therapeutic indications for IB004 remain undisclosed by the developer. It represents part of an emerging class of exosome-based therapies designed to address unmet medical needs through novel regenerative or modulatory mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IB004.